Loss of ZNF148 enhances insulin secretion in human pancreatic β cells

Insulin secretion from pancreatic beta cells is essential to the maintenance of glucose homeostasis. Defects in this process result in diabetes. Identifying genetic regulators that impair insulin secretion is crucial for the identification of novel therapeutic targets. Here, we show that reduction of ZNF148 in human islets, and its deletion in stem cell-derived beta cells (SC-beta cells), enhances insulin secretion. Transcriptomics of ZNF148-deficient SC-beta cells identifies increased expression of annexin and S100 genes whose proteins form tetrameric complexes involved in regulation of insulin vesicle trafficking and exocytosis. ZNF148 in SC-beta cells prevents translocation of annexin A2 from the nucleus to its functional place at the cell membrane via direct repression of S100A16 expression. These findings point to ZNF148 as a regulator of annexin-S100 complexes in human beta cells and suggest that suppression of ZNF148 may provide a novel therapeutic strategy to enhance insulin secretion.

Automated summary

Insulin secretion is essential for glucose homeostasis and defects in this process result in diabetes. Reduction of ZNF148 in human islets and its deletion in SC-beta cells enhance insulin secretion. ZNF148 in SC-beta cells prevents the translocation of annexin A2 from the nucleus to the cell membrane via repression of S100A16 expression, suggesting that suppression of ZNF148 may be a potential therapeutic strategy to enhance insulin secretion.